Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 6440-6446, December 1, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jaffrézou, J.-P.
Right arrow Articles by Laurent, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaffrézou, J.-P.
Right arrow Articles by Laurent, G.

Modulation of Subcellular Distribution of Doxorubicin in Multidrug-resistant P388/ADR Mouse Leukemia Cells by the Chemosensitizer {{2-Isopropyl-1-{4-[3-N-methyl-N-(3,4-dimethoxy-β-phenethyl)amino]propyloxy}-benzenesulfonyl}}indolizine1

Jean-Pierre Jaffrézou2, Thierry Levade, Pierre Chatelain and Guy Laurent

Laboratoire de Pharmacologie et de Toxicologie Fondamentales, Centre Nationale de la Recherche Scientifique [J. P. J. G. L.], Laboratoire de Biochimie Médicale, Centre Hospitalier Universitaire Rangueil [T. L.], and Service d'Hematologie, Centre Hospitalier Universitaire Purpan [G. L.], Toulouse, France, and Sanofi-Labaz Research Center, Brussels, Belgium [P. C.]

The impact of the novel chemosensitizer {{2-isopropyl-1-{4-[3-N-methyl-N-(3,4-dimethoxy-β-phenethyl)amino]propyloxy}benzenesulfonyl}}indolizine (SR33557) on the intracellular distribution of doxorubicin (DOX) within the multidrug-resistant murine P388/ADR leukemia cell line was studied by fluorescence microscopy. We found that under conditions which modulated multidrug-resistant (30 µm SR33557 for 1 h), P388/ADR cells presented an original sequestration of DOX in large intracellular vesicles, where SR33557 is itself sequestered, as seen by colocalization studies. Colocalization experiments with lysosomal and mitochondrial probes suggest that these vesicles are neither mitochondrial in nature nor functional lysosomes.

To investigate the biochemical basis for this effect, we studied the impact of SR33557 on the sphingolipid metabolism of P388/ADR cells. We observed that although P388/ADR cells normally catabolized exogenous [3H]sphingomyelin, when pretreated with SR33557 they showed almost complete inhibition of sphingomyelin breakdown. Finally, in order to demonstrate that the inability of P388/ADR cells to degrade sphingomyelin in the presence of SR33557 (which is a potent inhibitor of acid lysosomal sphingomyelinase) leads to phospholipid accumulation, we performed electron microscopy where we observed laminated inclusions. These morphological modifications are similar to those observed in Niemann-Pick disease lymphoblastoid cell lines which are inherently deficient in acid sphingomyelinase activity. The observation that, in the absence of SR33557, these Niemann-Pick disease cell lines presented similar DOX sequestration to that of SR33557-treated P388/ADR cells strongly suggests that DOX accumulates in SR33557-induced myeloid bodies. The redistribution of DOX within these vesicles, perhaps by preventing its expulsion by P-glycoprotein, may be a key in discovering the mechanism of action of SR33557.

1 This work was supported in part by Grants ARC 6891 and 6249 from l'Association pour la Recherche sur le Cancer, Sanofi, and l'Université Paul Sabatier of Toulouse, France.

2 Supported by a grant from La Ligue Nationale Contre le Cancer and in part by the Philippe Foundation, Inc. To whom requests for reprints should be addressed. Present address: Oncology Division, Room M-211, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305-5306.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 6/12/92. Accepted 9/18/92.




This article has been cited by other articles:


Home page
BloodHome page
C. Bezombes, S. Grazide, C. Garret, C. Fabre, A. Quillet-Mary, S. Muller, J.-P. Jaffrezou, and G. Laurent
Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains
Blood, August 15, 2004; 104(4): 1166 - 1173.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
R. Belhoussine, H. Morjani, J. M. Millot, S. Sharonov, and M. Manfait
Confocal Scanning Microspectrofluorometry Reveals Specific Anthracyline Accumulation in Cytoplasmic Organelles of Multidrug-resistant Cancer Cells
J. Histochem. Cytochem., December 1, 1998; 46(12): 1369 - 1376.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.